Novartis’ Cosentyx reduces synovitis in new psoriatic arthritis study
Novartis’ interleukin-17A (IL-17A) Cosentyx (secukinumab) demonstrated early synovitis reduction in patients with active psoriatic arthritis in the phase IIIb ULTIMATE study.
Synovitis, or joint lining inflammation, was assessed using Power Doppler ultrasonography (PDUS), an advanced and sensitive imaging technique.
The primary endpoint, which used a standardised ultrasound synovitis score (GLOESS), showed objectively significant benefit of Cosentyx compared to placebo on synovitis at week 12, with early improvement observed from week one, according to Novartis.
Cosentyx treatment also significantly improved key second endpoints versus placebo, the Swiss pharma company added.
In psoriatic arthritis (PsA), synovitis can lead to joint damage and if left untreated, this damage can be irreversible.
Read more: http://www.pharmatimes.com/news/novartis_cosentyx_reduces_synovitis_in_new_psoriatic_arthritis_study_1356011
Synovitis, or joint lining inflammation, was assessed using Power Doppler ultrasonography (PDUS), an advanced and sensitive imaging technique.
The primary endpoint, which used a standardised ultrasound synovitis score (GLOESS), showed objectively significant benefit of Cosentyx compared to placebo on synovitis at week 12, with early improvement observed from week one, according to Novartis.
Cosentyx treatment also significantly improved key second endpoints versus placebo, the Swiss pharma company added.
In psoriatic arthritis (PsA), synovitis can lead to joint damage and if left untreated, this damage can be irreversible.
Read more: http://www.pharmatimes.com/news/novartis_cosentyx_reduces_synovitis_in_new_psoriatic_arthritis_study_1356011